CL2019001329A1 - Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso. - Google Patents
Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.Info
- Publication number
- CL2019001329A1 CL2019001329A1 CL2019001329A CL2019001329A CL2019001329A1 CL 2019001329 A1 CL2019001329 A1 CL 2019001329A1 CL 2019001329 A CL2019001329 A CL 2019001329A CL 2019001329 A CL2019001329 A CL 2019001329A CL 2019001329 A1 CL2019001329 A1 CL 2019001329A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical compositions
- hydroxytrritpine
- receptor
- methods
- compositions modulating
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Abstract
LA PRESENTE INVENCIÓN DESCRIBE COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DERIVADOS DE LACTONA FUNCIONALIZADOS, PARA SU USO EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON LA DESREGULACIÓN DE LA ACTIVIDAD DEL RECEPTOR 7 DE 5-HIDROXITRIPTAMINA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662422344P | 2016-11-15 | 2016-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001329A1 true CL2019001329A1 (es) | 2019-08-30 |
Family
ID=62146107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001329A CL2019001329A1 (es) | 2016-11-15 | 2019-05-15 | Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso. |
Country Status (15)
Country | Link |
---|---|
US (3) | US10858368B2 (es) |
EP (1) | EP3541790A4 (es) |
JP (1) | JP7107955B2 (es) |
KR (2) | KR102590403B1 (es) |
CN (1) | CN110177776A (es) |
AU (2) | AU2017361078B2 (es) |
BR (1) | BR112019009908A2 (es) |
CA (1) | CA3043319A1 (es) |
CL (1) | CL2019001329A1 (es) |
EA (1) | EA201990915A1 (es) |
IL (3) | IL309982A (es) |
MX (2) | MX2019005603A (es) |
UA (1) | UA125631C2 (es) |
WO (1) | WO2018093818A1 (es) |
ZA (1) | ZA202105774B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014164756A1 (en) | 2013-03-11 | 2014-10-09 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
US10544117B2 (en) | 2014-09-10 | 2020-01-28 | Temple University—Of the Commonwealth System of Higher Education | 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
CN110177776A (zh) | 2016-11-15 | 2019-08-27 | 英联邦高等教育系统坦普尔大学 | 5-羟色胺受体7的新型调节剂及其使用方法 |
US10961249B2 (en) | 2017-03-21 | 2021-03-30 | Temple University-Of The Commonwealth System Of Higher Education | Modulators of the sigma-2 receptor and their method of use |
US11220505B2 (en) * | 2017-03-21 | 2022-01-11 | Temple University-Of The Commonwealth System Of Higher Education | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents |
EP4058458A2 (en) * | 2019-11-13 | 2022-09-21 | Temple University - Of The Commonwealth System of Higher Education | Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
KR20220113702A (ko) * | 2019-11-13 | 2022-08-16 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 5-하이드록시트립타민 수용체 7의 조절인자로서의 신규한 관능화된 락탐 및 이의 사용 방법 |
TW202328148A (zh) * | 2021-09-22 | 2023-07-16 | 日商塩野義製藥股份有限公司 | 具有血清素受體結合活性之螺雜環衍生物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040064499A1 (en) | 2002-09-26 | 2004-04-01 | Kasra Kasravi | Method and system for active knowledge management |
EP1592772A2 (en) | 2003-01-31 | 2005-11-09 | Pfizer Products Incorporated | 5ht7 antagonists and inverse agonists |
KR100843053B1 (ko) * | 2004-01-16 | 2008-07-01 | 에프. 호프만-라 로슈 아게 | 중추 신경계 질환의 치료를 위한 5-하이드록시트립트아민수용체(5-ht)의 조절제로서1-벤질-5-피페라진-1-일-3,4-다이하이드로-1h-퀴나졸린-2-온 유도체 및 각각의1h-벤조(1,2,6)티아다이아진-2,2-다이옥사이드 및1,4-다이하이드로-벤조(d)(1,3)옥사진-2-온 유도체 |
WO2007019083A1 (en) * | 2005-08-04 | 2007-02-15 | Janssen Pharmaceutica N.V. | Pyrimidine compounds as serotonin receptor modulators |
EP1875899A1 (en) | 2006-06-29 | 2008-01-09 | Laboratorios Del Dr. Esteve, S.A. | Use of 5HT7 receptor agonists for the treatment of pain |
US7910588B2 (en) | 2007-10-12 | 2011-03-22 | Eli Lilly And Company | 5-HT7 receptor antagonists |
US7902091B2 (en) | 2008-08-13 | 2011-03-08 | Varian Semiconductor Equipment Associates, Inc. | Cleaving of substrates |
WO2010028207A2 (en) | 2008-09-05 | 2010-03-11 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
WO2010069390A1 (en) | 2008-12-19 | 2010-06-24 | Nokia Siemens Networks Oy | Method and device for data processing in an udwdm network and communication system comprising such device |
US8637263B1 (en) * | 2010-10-14 | 2014-01-28 | Epiomed Therapeutics, Inc. | Assay for determination of compounds having anti-emetic activity |
WO2012058769A1 (en) | 2010-11-03 | 2012-05-10 | Mcmaster University | Method of treating mucosal inflammation |
WO2013154513A1 (en) * | 2012-04-04 | 2013-10-17 | Mi̇lli̇ Savunma Bakanliği | The use of 5-ht7 receptor antagonists including some atypical antipsychotics as antipruritic agents |
US9464062B2 (en) * | 2012-11-28 | 2016-10-11 | Temple University—Of the Commonwealth System of Higher Education | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators |
WO2014164756A1 (en) * | 2013-03-11 | 2014-10-09 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
US10544117B2 (en) | 2014-09-10 | 2020-01-28 | Temple University—Of the Commonwealth System of Higher Education | 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
WO2016183150A1 (en) | 2015-05-12 | 2016-11-17 | Temple University-Of The Commonwealth System Of Higher Education | Novel sigma-2 receptor binders and their method of use |
CN110177776A (zh) | 2016-11-15 | 2019-08-27 | 英联邦高等教育系统坦普尔大学 | 5-羟色胺受体7的新型调节剂及其使用方法 |
US11220505B2 (en) | 2017-03-21 | 2022-01-11 | Temple University-Of The Commonwealth System Of Higher Education | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents |
US10961249B2 (en) | 2017-03-21 | 2021-03-30 | Temple University-Of The Commonwealth System Of Higher Education | Modulators of the sigma-2 receptor and their method of use |
CN112437768A (zh) | 2018-05-11 | 2021-03-02 | 英联邦高等教育系统坦普尔大学 | 作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法 |
-
2017
- 2017-11-15 CN CN201780079945.9A patent/CN110177776A/zh active Pending
- 2017-11-15 WO PCT/US2017/061677 patent/WO2018093818A1/en unknown
- 2017-11-15 CA CA3043319A patent/CA3043319A1/en active Pending
- 2017-11-15 IL IL309982A patent/IL309982A/en unknown
- 2017-11-15 MX MX2019005603A patent/MX2019005603A/es unknown
- 2017-11-15 JP JP2019547227A patent/JP7107955B2/ja active Active
- 2017-11-15 US US16/349,811 patent/US10858368B2/en active Active
- 2017-11-15 IL IL291029A patent/IL291029B1/en unknown
- 2017-11-15 BR BR112019009908A patent/BR112019009908A2/pt unknown
- 2017-11-15 KR KR1020197016744A patent/KR102590403B1/ko active IP Right Grant
- 2017-11-15 EP EP17871446.5A patent/EP3541790A4/en active Pending
- 2017-11-15 KR KR1020237034770A patent/KR20230148384A/ko not_active Application Discontinuation
- 2017-11-15 EA EA201990915A patent/EA201990915A1/ru unknown
- 2017-11-15 AU AU2017361078A patent/AU2017361078B2/en active Active
- 2017-11-15 UA UAA201906703A patent/UA125631C2/uk unknown
-
2019
- 2019-05-06 IL IL266483A patent/IL266483B/en unknown
- 2019-05-14 MX MX2022009907A patent/MX2022009907A/es unknown
- 2019-05-15 CL CL2019001329A patent/CL2019001329A1/es unknown
-
2020
- 2020-09-09 US US17/015,696 patent/US11319327B2/en active Active
-
2021
- 2021-08-13 ZA ZA2021/05774A patent/ZA202105774B/en unknown
-
2022
- 2022-03-31 US US17/709,847 patent/US20230112888A1/en active Pending
- 2022-04-04 AU AU2022202240A patent/AU2022202240B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2022009907A (es) | 2022-08-25 |
AU2022202240A1 (en) | 2022-04-28 |
IL291029A (en) | 2022-05-01 |
KR20230148384A (ko) | 2023-10-24 |
US10858368B2 (en) | 2020-12-08 |
UA125631C2 (uk) | 2022-05-04 |
US11319327B2 (en) | 2022-05-03 |
CA3043319A1 (en) | 2018-05-24 |
IL266483B (en) | 2022-04-01 |
US20210238189A1 (en) | 2021-08-05 |
EA201990915A1 (ru) | 2019-11-29 |
IL266483A (en) | 2019-07-31 |
JP7107955B2 (ja) | 2022-07-27 |
EP3541790A4 (en) | 2020-06-17 |
AU2022202240B2 (en) | 2024-03-21 |
KR102590403B1 (ko) | 2023-10-16 |
KR20190097006A (ko) | 2019-08-20 |
JP2019535825A (ja) | 2019-12-12 |
AU2017361078B2 (en) | 2022-01-06 |
CN110177776A (zh) | 2019-08-27 |
MX2019005603A (es) | 2019-10-14 |
AU2017361078A1 (en) | 2019-05-30 |
JP2022132444A (ja) | 2022-09-08 |
US20230112888A1 (en) | 2023-04-13 |
IL309982A (en) | 2024-03-01 |
BR112019009908A2 (pt) | 2019-08-13 |
EP3541790A1 (en) | 2019-09-25 |
ZA202105774B (en) | 2022-07-27 |
US20190367528A1 (en) | 2019-12-05 |
WO2018093818A1 (en) | 2018-05-24 |
IL291029B1 (en) | 2024-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001329A1 (es) | Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso. | |
CO2019012353A2 (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1 | |
CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2019003735A (es) | Formulaciones diluibles de cannabinoides y procesos para su preparacion. | |
SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
CL2018003265A1 (es) | Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
GT201700223A (es) | Imidazopirazinonas como inhibidores de pde 1 | |
CL2016002257A1 (es) | Anticuerpos anti-mcam y métodos de uso asociados | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
CL2019002251A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. | |
GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
CL2019001330A1 (es) | Inhibidores de la tirosina quinasa de bruton. | |
CU20170018A7 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo | |
CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
CL2018001085A1 (es) | Derivados de indolin-2-ona | |
CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
DOP2016000263A (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 |